A sumatriptan iontophoretic transdermal system for the acute treatment of migraine

Headache

Volumn 52, Issue 9, 2012, Pages 1402-1410

  Goldstein, Jerome ^a   Smith, Timothy R ^b   Pugach, Neil ^c   Griesser, Jim ^d   Sebree, Terri ^e   Pierce, Mark ^e  

^a San Francisco Clinical Research Center   (United States)

^b Mercy Clinic Headache Center   (United States)

^c Brighton Research Group   (United States)

^d Griesser Group   (United States)

^e NuPathe Inc   (United States)

Author keywords

iontophoresis; migraine; sumatriptan

Indexed keywords

SUMATRIPTAN;

ANALGESIA; APPLICATION SITE PAIN; APPLICATION SITE PARESTHESIA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; NAUSEA; PHASE 3 CLINICAL TRIAL; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL PATCH;

ADULT; ANALGESICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IONTOPHORESIS; MALE; MIGRAINE DISORDERS; SUMATRIPTAN; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 84867096309     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2012.02198.x     Document Type: Article

References (20)

1. Lipton RB, Stewart WF, Diamond S, et al,. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001; 41: 646-657.
2. Silberstein SD,. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55: 754-762.
3. Goldstein J,. Migraine management. Focus on meeting patients' individual needs. Postgrad Med. 2005; 117: 17-25.
4. Silberstein SD,. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache. 1995; 35: 387-396.
5. Buse DC, Reed ML, Fanning KM, et al,. Frequent nausea in episodic migraine is common and associated with increased burden: Results from the AMPP study. American Headache Society Annual Scientific Meeting, Washington, DC, 2011.
6. Matchar DB, Young WB, Rosenberg JH, et al,. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Available at: http://www.aan.com/professionals/practice/pdfs/ gl0087.pdf (accessed June 7, 2012).
7. Rapoport AM, Tepper SJ, Bigal ME, et al,. The triptan formulations: How to match patients and products. CNS Drugs. 2003; 17: 431-447.
8. Fuseau E, Petricoul O, Moore KHP, et al,. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet. 2002; 41: 801-811.
9. Uemura N, Onishi T, Mitaniyama A, et al,. Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Investig. 2005; 25: 199-208.
10. Pierce M, Marbury T, O'Neill C, et al,. Zelrix: A novel transdermal formulation of sumatriptan. Headache. 2009; 49: 817-825.
11. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004; 24: 14-150.
12. Siegel SJ, O'Neill C, Dube LM, et al,. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res. 2007; 24: 1919-1926.
13. Mathew NT, Loder EW,. Evaluating the triptans. Am J Med. 2005; 118 (Suppl. 1): 28S-35S.
14. Tfelt-Hansen P, Block G, Dahlof C, et al,. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000; 20: 765-786.
15. Loder E,. Triptan therapy in migraine. N Engl J Med. 2010; 363: 63-70.
16. Aurora SK, Kori SH, Barrodale P, et al,. Gastric stasis in migraine: More than just a paroxysmal abnormality during a migraine attack. Headache. 2006; 46: 57-63.
17. Ferrari A, Pinetti D, Bertolini A, et al,. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur J Clin Pharmacol. 2008; 64: 489-495.
18. Batheja P, Thakur R, Michniak B,. Transdermal iontophoresis. Expert Opin Drug Deliv. 2006; 3: 127-138.
19. Prausnitz MR, Langer R,. Transdermal drug delivery. Nat Biotechnol. 2008; 26: 1261-1268.
20. Brown MB, Martin GP, Jones SA, et al,. Dermal and transdermal drug delivery systems: Current and future prospects. Drug Deliv. 2006; 13: 175-187.